Cerenome Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Cerenome sono diminuiti a un tasso medio annuo di -7%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 33.4%. I ricavi sono cresciuti crescere a un tasso medio annuo di 44.8%.
Informazioni chiave
-7.02%
Tasso di crescita degli utili
57.40%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.04% |
| Tasso di crescita dei ricavi | 44.82% |
| Rendimento del capitale proprio | -477.54% |
| Margine netto | -620.70% |
| Ultimo aggiornamento sugli utili | 30 Jun 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento narrativa • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.
Aggiornamento narrativa • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.
Aggiornamento narrativa • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.Aggiornamento narrativa • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.Aggiornamento narrativa • May 24
PSTV: Future Brain Cancer CPT Codes Could Reprice Shares Despite Recent Downgrades
Analysts have cut their price target on Plus Therapeutics by $25.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples following recent downgrades and target revisions. Analyst Commentary Recent research notes highlight a shift in how analysts frame the risk and reward around Plus Therapeutics.Aggiornamento narrativa • May 02
PSTV: CNS Delivery And New CPT Codes Will Drive Future Upside
Analysts have adjusted their view on Plus Therapeutics, cutting the average price target by $25.50 while updating their models for fair value, discount rate, profit margin and future P/E to reflect a mix of rating changes and new coverage. Analyst Commentary Recent Street research on Plus Therapeutics reflects a mix of optimism about long term potential and caution around execution and valuation, with one firm initiating coverage positively and others resetting expectations through a downgrade and a lower price target.Aggiornamento narrativa • Apr 18
PSTV: Future Brain Cancer CPT Codes And Delivery Technique Could Reprice Shares
Narrative Update The updated analyst price target for Plus Therapeutics moves from about $475 to roughly $65, as analysts cite recent target cuts and a downgrade, along with one newer bullish initiation that together lead to a more tempered but still constructive set of assumptions on revenue growth, margins, and future P/E. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of caution and optimism, with several firms trimming targets and one newer, more constructive initiation helping to reset expectations rather than support extreme outcomes.Aggiornamento narrativa • Apr 03
PSTV: Future Brain Cancer CPT Code And FDA Dialogue Could Reprice Shares
The analyst price target for Plus Therapeutics has shifted from $20.50 to $475.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E. This change is informed by recent mixed Street research that includes a downgrade from D.Aggiornamento narrativa • Mar 20
PSTV: Upcoming CNS Milestones And New CPT Code Will Shape Upside Potential
Narrative Update on Plus Therapeutics Analysts have trimmed their price targets on Plus Therapeutics by about $1 to $1.50, reflecting revised views on profit margin potential and valuation, while still citing supportive research coverage for the story. Analyst Commentary Recent research updates paint a mixed picture for Plus Therapeutics, with one initiation taking a constructive stance and other reports trimming price targets by $1 to $1.50.Aggiornamento narrativa • Mar 06
PSTV: FDA Pivotal Trial Design And Brain Cancer Pipeline Will Drive Upside
Analysts have reduced their blended price target on Plus Therapeutics by about $0.60, reflecting updated views on fair value, revenue growth expectations, profit margins, and future P/E following recent initiations and target changes from several firms. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of views, with some firms starting coverage positively while others are taking a more conservative stance through reduced price targets.Aggiornamento narrativa • Feb 19
PSTV: Upcoming CNS Milestones And Diagnostics Rollout Will Drive Future Upside
Analysts have trimmed their average Plus Therapeutics price target by $2.50, citing updated assumptions around discount rates, profit margins and a higher future P/E multiple, while still maintaining their fair value estimate at $5.50. Analyst Commentary Bullish Takeaways Bullish analysts point to enough upside against the current trading price to justify a fresh positive view, even after trimming inputs such as discount rates and profit margins.Aggiornamento narrativa • Feb 05
PSTV: Upcoming CNS Trials And Diagnostics Expansion Will Drive Upside Potential
Analysts have revised their price targets for Plus Therapeutics lower, with the implied fair value estimate moving from about $9.67 to $5.50 as they incorporate updated assumptions for revenue growth, profit margins, discount rates, and a lower future P/E multiple following recent research updates. Analyst Commentary Recent research updates offer a mixed picture of how analysts are thinking about Plus Therapeutics, with some seeing attractive upside potential and others tempering expectations through lower price targets.Aggiornamento narrativa • Jan 22
PSTV: FDA Pivotal Trial Progress Will Drive Future Upside Potential
Narrative Update on Plus Therapeutics Analysts have adjusted their price target for Plus Therapeutics to US$1.63. The change is linked to updated assumptions for discount rate, revenue growth, profit margin, and a revised forward P/E of 49.25x, which reflect their refreshed outlook on the company’s risk and earnings potential.Aggiornamento narrativa • Jan 06
PSTV: Advancing Central Nervous System Cancer Trials And Grant Funding Will Drive Upside Potential
Analysts have raised their price target on Plus Therapeutics to US$1.63 per share, reflecting updated assumptions that now pair a revenue growth estimate of 96.95% with a slightly higher discount rate of 7.18%, a lower future P/E of 51.69x, and a modestly adjusted profit margin outlook of 16.24%. What's in the News Presented three clinical data updates at the WFNOS/SNO Annual Meeting in Honolulu covering multiple doses of Rhenium (186Re) Obisbemeda (Reyobiq) for leptomeningeal metastases, including rationale, design, and preliminary Cohort 1 data (Key Developments).Aggiornamento narrativa • Dec 15
PSTV: Expanded Brain Cancer Pipeline And Funding Will Drive Upside Potential
Narrative Update on Plus Therapeutics Analysts have raised their price target on Plus Therapeutics to approximately 83.96 from about 114.72, citing a modestly higher assumed discount rate, slightly lower long term profit margins, and somewhat stronger revenue growth expectations that together point to a more balanced, though still optimistic, valuation profile. What's in the News Presented three positive clinical data updates at the WFNOS/SNO Annual Meeting, including early ReSPECT-LM multidose trial results showing REYOBIQ was well tolerated at initial dosing levels and supporting continued dose optimization for leptomeningeal metastases patients (company announcement).Aggiornamento narrativa • Nov 04
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Analysts have raised their fair value estimate for Plus Therapeutics from $7.88 to $9.67, citing updated revenue forecasts and improved capital structure following recent changes in financing. Analyst Commentary Analyst updates on Plus Therapeutics reflect a balanced perspective on the company’s outlook and recent financing changes.Aggiornamento narrativa • Sep 04
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Analysts lowered their price target for Plus Therapeutics from $8.83 to $7.88 primarily due to anticipated equity dilution from recent financing, which increased outstanding shares and warrants, though they remain positive on the company’s long-term outlook. Analyst Commentary Price target reductions reflect anticipated equity dilution following recent financing activities.Articolo di analisi • Aug 15
We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully
NasdaqCM:PSTV 1 Year Share Price vs Fair Value Explore Plus Therapeutics's Fair Values from the Community and select...
Nuova narrativa • Apr 20
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Cerenome guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 26 | 4 | -26 | 18 | 0 |
| 31 Mar 26 | 5 | -12 | 15 | 0 |
| 31 Dec 25 | 5 | -22 | 12 | 0 |
| 30 Sep 25 | 5 | -21 | 11 | 0 |
| 30 Jun 25 | 5 | -19 | 10 | 0 |
| 31 Mar 25 | 5 | -23 | 11 | 0 |
| 31 Dec 24 | 6 | -13 | 10 | 0 |
| 30 Sep 24 | 6 | -13 | 9 | 0 |
| 30 Jun 24 | 6 | -13 | 9 | 0 |
| 31 Mar 24 | 6 | -12 | 9 | 0 |
| 31 Dec 23 | 5 | -13 | 9 | 0 |
| 30 Sep 23 | 4 | -15 | 10 | 0 |
| 30 Jun 23 | 3 | -17 | 10 | 0 |
| 31 Mar 23 | 1 | -21 | 10 | 0 |
| 31 Dec 22 | 0 | -20 | 10 | 0 |
| 30 Sep 22 | 0 | -19 | 9 | 0 |
| 30 Jun 22 | 0 | -17 | 8 | 0 |
| 31 Mar 22 | 0 | -15 | 8 | 0 |
| 31 Dec 21 | 0 | -13 | 7 | 0 |
| 30 Sep 21 | 0 | -13 | 7 | 0 |
| 30 Jun 21 | 0 | -11 | 6 | 0 |
| 31 Mar 21 | 0 | -10 | 6 | 0 |
| 31 Dec 20 | 0 | -8 | 6 | 0 |
| 30 Sep 20 | 1 | -4 | 6 | 0 |
| 30 Jun 20 | 6 | -2 | 6 | 0 |
| 31 Mar 20 | 6 | -2 | 5 | 0 |
| 31 Dec 19 | 7 | -4 | 5 | 0 |
| 30 Sep 19 | 7 | -7 | 5 | 0 |
| 30 Jun 19 | 2 | -11 | 5 | 0 |
| 31 Mar 19 | 2 | -9 | 5 | 0 |
| 31 Dec 18 | 3 | -11 | 6 | 0 |
| 30 Sep 18 | 4 | -18 | 7 | 0 |
| 30 Jun 18 | 5 | -19 | 8 | 0 |
| 31 Mar 18 | 6 | -24 | 10 | 0 |
| 31 Dec 17 | 6 | -27 | 11 | 0 |
| 30 Sep 17 | 8 | -23 | 11 | 0 |
| 30 Jun 17 | 9 | -24 | 12 | 0 |
| 31 Mar 17 | 10 | -24 | 12 | 0 |
| 31 Dec 16 | 11 | -22 | 12 | 0 |
| 30 Sep 16 | 12 | -20 | 12 | 0 |
| 30 Jun 16 | 12 | -13 | 12 | 0 |
| 31 Mar 16 | 12 | -2 | 12 | 0 |
| 31 Dec 15 | 12 | -19 | 12 | 0 |
| 30 Sep 15 | 12 | -24 | 14 | 0 |
Guadagni di qualità: CNSY al momento non è redditizia.
Margine di profitto in crescita: CNSY al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: CNSY non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 7% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di CNSY nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: CNSY non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 64.6% ).
Rendimento del capitale proprio
ROE elevato: CNSY ha un Return on Equity negativo ( -477.54% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/21 03:45 |
| Prezzo dell'azione a fine giornata | 2026/09/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cerenome, Inc. è coperta da 11 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Andrew D'Silva | B. Riley Securities, Inc. |
| John Savin | Edison Investment Research |